Skip to main content

Table 4 Variables independently related to adverse events in the total study populations (368 patients): Cox proportional hazard univariate and multivariate analysis

From: Does treatment assignment influence the prognosis of patients with symptomatic severe aortic stenosis?

Variables Values of patients with vs without events HR univariate analysis CI p HR multivariate analysis CI p
LV ejection fraction (%) 44 ± 14 vs 52 ± 13 0.96 0.95-0.98 &0.001 0.98 0.96-0.99 0.003
History of heart failure (%) 87 vs 66 1.65 1.28-2.13 &0.001 2.25 1.16-4.34 0.02
GFR (ml/min/1.73/m2) 43 ± 24 vs 63 ± 27 0.98 0.97-0.99 &0.001 0.98 0.97-0.99 0.01
Absolute contraindication to AVR (%) 57 vs 27 3.58 2.16-5.94 &0.001 2.39 1.35-4.22 0.003
Treatment assignment for AS - 2.01 1.62-2.62 &0.001 1.82 1.10-3.25 &0.001
Age (year) 83 ± 8 vs 77 ± 9 1.02 1.01-1.03 0.004 1.05 0.99-1.09 0.07
NYHA functional class (1–4) 2.8 ± 0.7 vs 2.5 ± 0.07 2.02 1.41-2.90 &0.001 1.05 0.81-1.36 0.69
Charlons co-morbidity index 3.9 ± 1.7 vs 2.7 ± 1.8 1.29 1.18-1.42 &0.001 1.25 0.90-1.57 0.60
Katz score 4.1 ± 1.8 vs 3.1 ± 1.9 1.33 1.11-1.55 &0.001 1.31 0.85-1.62 0.52
Aortic valve area (cm2/m2) 0.61 ± 0.18 vs 0.69 ± 0.20 1.44 0.45-4.41 0.52 0.18 0.01-2.82 0.22
Peripheral artery disease (%) 10 vs 3 3.63 1.32-9.99 0.01 2.36 0.71-7.84 0.16
COPD (%) 36 vs 18 2.48 1.45-4.25 0.01 1.02 0.36-2.84 0.97
Cancer (%) 8 vs 2 1.90 1.11-3.25 0.02 1.07 0.49-2.33 0.87
EuroSCORE (points) 34 ± 22 vs 22 ± 18 1.03 1.02-1.04 &0.001 0.99 0.98-1.01 0.63
ACEi/ARB (%) 49 vs 66 0.48 0.28-0.81 0.006 0.56 0.31-1.01 0.08
Beta-blockers (%) 22 vs 37 0.48 0.26-0.88 0.02 0.57 0.29-1.15 0.12
  1. AS = aortic stenosis; AVR = aortic valve replacement; COPD = chronic obstructive pulmonary disease; GFR = glomerular filtration rate; LV = left ventricular; NYHA = New York Heart Association.